Locally Advanced Triple-Negative Breast Carcinoma
5 clinical trials · Condition
◉ Watch Locally Advanced Triple-Negative Breast Carcinoma
| Record | Firm | Date |
|---|---|---|
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer (NCT06324240) | Emory University | 2025-12-02 |
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (NCT06590558) | National Cancer Institute (NCI) | 2025-08-04 |
| A Study of Pembrolizumab and Cryoablation in People With Breast Cancer (NCT06246968) | Memorial Sloan Kettering Cancer Center | 2024-01-29 |
| Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer (NCT05422794) | National Cancer Institute (NCI) | 2023-05-18 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (NCT05269381) | Mayo Clinic | 2022-03-31 |
Track Locally Advanced Triple-Negative Breast Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.